Tran Van Cong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tran Van Cong has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Dang Minh Quang
Sarcoma Center, Vinmec Times City, Vinmec International Hospital, Hanoi, Vietnam
1 shared publication - Dung Tran Trung
Sarcoma Center, Vinmec Times City, Vinmec International Hospital, Hanoi, Vietnam
1 shared publication - Duong Quang Vinh
Department of Surgery, Vinmec Phu Quoc, Vinmec International Hospital, Phu Quoc, Vietnam
1 shared publication - Le Duc Huy
Sarcoma Center, Vinmec Times City, Vinmec International Hospital, Hanoi, Vietnam
1 shared publication - Le The Hung
Sarcoma Center, Vinmec Times City, Vinmec International Hospital, Hanoi, Vietnam
1 shared publication - Luong Nhat Anh
Sarcoma Center, Vinmec Times City, Vinmec International Hospital, Hanoi, Vietnam
1 shared publication
Latest Publications
- Open Access
- 12 August 2026
- Published by Springer Nature in Archives of orthopaedic and trauma surgery
- Vol. 146 (1) , 297
Liquid nitrogen-treated autograft combined with megaprosthesis versus total femoral replacement for large-volume malignant femoral bone tumors: a comparative study
Background: Limb-salvage surgery for extensive femoral osteosarcoma presents major reconstructive challenges. Conventional options such as total femoral replacement (TFR) and long-segment biological reconstructions are associated with significant complications. We evaluated the clinical outcomes of a novel hybrid approach combining a liquid nitrogen-treated autograft with a megaprosthesis (LN-MP) and compared them with those of TFR. Materials and methods: This retrospective study included 28 patients (range 8–24 years old) with malignant femoral bone tumors treated between 2020 and 2024. Patients underwent either LN-MP (n = 10) or TFR (n = 18). Perioperative outcomes, functional results (Musculoskeletal Tumor Society score—MSTS), bone union, oncological control, and survival were analyzed. Results: LN-MP demonstrated better functional outcomes (MSTS 27.0 ± 2.1 vs. 24.4 ± 2.2, p = 0.014), shorter operative time, and lower blood loss compared with TFR. Length of stay and follow-up duration were comparable. Continuous disease-free survival was higher in the LN-MP group (90% vs. 44%, p = 0.058), with lower recurrence (10% vs. 28%). Bone union was achieved in 70% of LN-MP cases at a mean of 9 months, with longer graft length associated with delayed union. Conclusions: LN-MP reconstruction may serve as a joint-preserving alternative to total femoral replacement for patients with extensive malignant femoral tumors. In this preliminary series, LN-MP was associated with favorable functional outcomes, satisfactory graft-host bone union, and acceptable oncological results. Given the retrospective design, limited sample size, and short follow-up duration, further studies with larger cohorts and longer follow-up are required to define the role of LN-MP among contemporary limb-salvage reconstructive strategies. Level of evidence: Therapeutic, Level III: retrospective comparative cohort study.
- 12 August 2026
- Published by Springer Nature in Archives of orthopaedic and trauma surgery
- Vol. 146 (1) , 297
Open AccessLiquid nitrogen-treated autograft combined with megaprosthesis versus total femoral replacement for large-volume malignant femoral bone tumors: a comparative study
Background: Limb-salvage surgery for extensive femoral osteosarcoma presents major reconstructive challenges. Conventional options such as total femoral replacement (TFR) and long-segment biological reconstructions are associated with significant complications. We evaluated the clinical outcomes of a novel hybrid approach combining a liquid nitrogen-treated autograft with a megaprosthesis (LN-MP) and compared them with those of TFR. Materials and methods: This retrospective study included 28 patients (range 8–24 years old) with malignant femoral bone tumors treated between 2020 and 2024. Patients underwent either LN-MP (n = 10) or TFR (n = 18). Perioperative outcomes, functional results (Musculoskeletal Tumor Society score—MSTS), bone union, oncological control, and survival were analyzed. Results: LN-MP demonstrated better functional outcomes (MSTS 27.0 ± 2.1 vs. 24.4 ± 2.2, p = 0.014), shorter operative time, and lower blood loss compared with TFR. Length of stay and follow-up duration were comparable. Continuous disease-free survival was higher in the LN-MP group (90% vs. 44%, p = 0.058), with lower recurrence (10% vs. 28%). Bone union was achieved in 70% of LN-MP cases at a mean of 9 months, with longer graft length associated with delayed union. Conclusions: LN-MP reconstruction may serve as a joint-preserving alternative to total femoral replacement for patients with extensive malignant femoral tumors. In this preliminary series, LN-MP was associated with favorable functional outcomes, satisfactory graft-host bone union, and acceptable oncological results. Given the retrospective design, limited sample size, and short follow-up duration, further studies with larger cohorts and longer follow-up are required to define the role of LN-MP among contemporary limb-salvage reconstructive strategies. Level of evidence: Therapeutic, Level III: retrospective comparative cohort study.